Pureos Bioventures

Pureos Bioventures is a specialized venture capital firm based in Küsnacht, Switzerland, dedicated to investing in innovative private biotech companies. Established as a relatively new entrant in the life sciences investment landscape, the firm has quickly made a significant impact by focusing on drug discovery and development across various therapeutic areas. Their strategic location in Switzerland provides them with access to a robust European biotech ecosystem, while their investment scope extends to promising companies in the United States as well.

TheThe firm successfully closed its inaugural fund, Pureos Bioventures Fund I, at CHF 200 million, demonstrating strong investor confidence in its focused strategy. Building on this momentum, Pureos Bioventures further solidified its position by closing its second fund, Pureos Bioventures Fund II, at an impressive CHF 330 million in 2023. This substantial capital base enables them to support companies from early-stage development through to growth stages. Pureos typically targets initial investments ranging from CHF 5 million to CHF 15 million, positioning themselves to be a lead or co-lead investor in their portfolio companies.

Pureos Bioventures distinguishes itself through a hands-on approach, leveraging the deep scientific and operational expertise of its team. The firm seeks to partner with entrepreneurial teams developing groundbreaking therapies, providing not just capital but also strategic guidance and access to their extensive network within the pharmaceutical and biotech industries. Their investment philosophy emphasizes rigorous scientific due diligence and a long-term commitment to fostering the growth of companies poised to bring transformative medicines to patients. They actively seek opportunities in areas of high unmet medical need, aiming to drive significant advancements in healthcare.